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Background. Negative margins are associated with a reduced risk of ipsilateral breast tumor recurrence (IBTR) in women with early
stage breast cancer treated with breast conserving surgery (BCS). Not infrequently, atypical ductal hyperplasia (ADH) is reported
as involving the margin of a BCS specimen, and there is no consensus among surgeons or pathologists on how to approach this
diagnosis resulting in varied reexcision practices among breast surgeons. The purpose of this paper is to establish a reasonable
approach to guide the treatment of ADH involving the margin after BCS for early stage breast cancer. Methods. the published
literature was reviewed using the PubMed site from the US National Library of Medicine. Conclusions. ADH at the margin of
a BCS specimen performed for early stage breast cancer is a controversial pathological diagnosis subject to large interobserver
variability. There is not enough data evaluating this diagnosis to change current practice patterns; however, it is reasonable to
consider reexcision for ADH involving a surgical margin, especially if it coexists with low grade DCIS. Further studies with longer
followup and closer attention to ADH at the margin are needed to formulate treatment guidelines.
1. Introduction
Breast conserving surgery (BCS) is a widely accepted treat-
ment option for early-stage breast cancer based on several
prospective, randomized trials that demonstrate equivalent
survival after BCS compared to that after mastectomy [1–
7]. The recent 20-year followup of the NSABP B-06 trial
recognizes an increased risk of ipsilateral breast tumor
recurrence (IBTR) after BCS; however, this risk is decreased
with the addition of whole breast irradiation and obtaining
negative margins [1]. While the validation of BCS requires
that a negative margin be obtained, there is still no consensus
definition of what constitutes an adequate negative margin
width resulting in marked variation in BCS reexcision
practices among surgeons [8–10]. While all agree it is
not appropriate to have tumor cells involving the inked
margin, there is no compelling or consistent evidence to
indicate how widely free a margin should be [11–15].
Accordingly, margin width alone may not be sufficient to
prove adequacy of excision and qualitative and quantitative
pathologic characteristics of the cells within the margins
may be important to consider [16]. One of those factors
is proliferative lesions and in particular atypical ductal
hyperplasia (ADH) at the margin of BCS specimens [17].
Interestingly, despite the high volume of studies investigating
the question of adequate margin width, there is a paucity
of studies that address the pathological characteristics of the
cells within the margin. Not surprisingly, in the setting of no
evidence-based guidelines, neither pathologists nor surgeons
know what to do with the diagnosis of ADH involving a
margin of a BCS specimen performed for early-stage breast
cancer [18–20]. The purpose of this paper is to address
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the significance of a diagnosis of ADH at the margin and
evaluate if there is evidence to guide the surgical decision for
reexcision.
2. Methods
We searched the PubMed database for studies evaluat-
ing atypical ductal hyperplasia published in English with
no date range qualification. We searched Medical Sub-
ject Headings (MESH), titles, and abstracts for the terms
atypical ductal hyperplasia (ADH), breast conserving ther-
apy (BCS), ADH at margin, proliferative lesion of the
breast, ipsilateral breast tumor recurrence (IBTR). All
major studies evaluating margin status and IBTR after BCS
were evaluated for purposeful attention to ADH at the
margin.
3. Results
3.1. Atypical Ductal Hyperplasia: A Histopathologic Prospec-
tive. Atypical ductal hyperplasia (ADH) is an atypical pro-
liferative lesion that falls in between the continuum from
normal hyperplasia to low grade ductal carcinoma in situ
(LG-DCIS). There is currently no general agreement on
quantitative versus morphologic criteria to separate ADH
from DCIS. However, some define ADH as the cells with
morphologic characteristics of LG-DCIS (i.e., a cribiform
or micropapillary proliferation of uniform cells with low-
grade nuclei) with partial involvement of the terminal
duct lobular unit (TDLU) or involvement in less than
2 separate duct spaces or less than 2mm in aggregate
diameter [17, 24–26]. This is a purely quantitative and
not a biologic distinction [27, 28], and as such it can
be a subjective diagnosis in practice. A recent review
acknowledged differentiation between ADH and LG DCIS
is one of the most challenging areas in diagnostic pathology
[28]. Consequently, the diagnosis has proven vulnerable to
a large interobserver variability even between highly trained
breast pathologists in optimal conditions as demonstrated
in multiple studies [18, 21–23]. Table 1 demonstrates the
differing rates of agreement between pathologists observed
in 3 well-known studies that investigated concordance rates
among pathologists interpreting proliferative lesions. Rosai
[21] and Jain et al. [23] found complete agreement amongst
pathologists deciphering ADH from DCIS only 0% and 32%
of the time, respectively. Schnitt et al. [22] found slightly
improved agreement after diagnostic criteria for proliferative
lesions was provided to the pathologists prior to slide
interpretation, but still only found all pathologists agreed
<60% of the time when diagnosing a lesion as DCIS versus
ADH. A recent study by Ghofrani et al. [18] is consistent
with this phenomenon. They sent a single diagram depicting
a partially involved duct adjacent to unequivocal DCIS to 230
pathologists known for their expertise in breast pathology
and asked them to interpret the diagrammatic representa-
tion. When looking at the exact same lesion, 56.5% of the
pathologists considered it ADH and 43.5% interpreted it as
DCIS.
3.2. Significance of ADH. It is well established in the literature
and in practice that the diagnosis of ADH on core needle
biopsy (CNB) necessitates a subsequent excisional biopsy
[19]. This recommendation is based on the difficult patho-
logic distinction between ADH and LG DCIS especially in
settings of small tissue samples, and also the fact that ADH
on CNB is associated with a high degree of upstaging to in
situ and invasive cancer on subsequent excisions at published
rates varying between 24 and 45% [29]. Historically, ADH
was considered only a risk factor of subsequent cancer
conferring a 4-5x increased risk of invasive carcinoma in
either breast [30]; however, recent studies have challenged
this and provided some genetic and molecular evidence that
ADH is a precursor to a low grade cancer [27, 31]. When
ADH is diagnosed in the setting of a knownDCIS or invasive,
some pathologists report it as a distinct lesion from ADH
diagnosed independent of a neoplastic lesion. In a study by
Lennington et al. [32] that investigated patterns of DCIS, the
authors found that ADH associated with DCIS located at the
periphery of the lesion; thus, indicating that when ADH is at
the margin of a BCS specimen, it likely represents the most
peripheral extent of the neoplastic lesion. Goldstein agrees
with this concept when he describes a foci of ADH identified
near the margin of an excision specimen for DCIS or
invasive carcinoma represents partial involvement of lobules
by intraluminal neoplastic cells and is the farthest tentacular
extension of low-grade intraductal carcinoma [17].
3.3. ADH at the Margin of a BCS Specimen for Early Stage
Breast Cancer: Current Trends among Surgeons and Pathol-
ogists. Nizre et al. [19] conducted an important survey
capturing the current management of breast borderline
lesions. The survey was sent to members of the American
Society of Breast Surgeons (ASBS).Responses from 477
surgeons were received and analyzed. Importantly, 337 of
the respondents dedicated more than 50% of their practice
to breast surgery and 50% were from academic, cancer
center, or dedicated breast centers. When asked about how to
manage a diagnosis of ADHwithin 1mm of a BCS specimen,
61% favored no further surgery while 30% recommended
selective reexcision. Interestingly, the amount of training
affected response tendencies towards no further surgery.
For example, among surgeons practicing at a cancer center,
80% would recommend no further surgery, 20% would
recommend selective reexcision, and 0% recommended
routine reexcision when ADH involved the margin. This is
compared to private practice where 54% would recommend
no further surgery, 40% would selectively reexcise, and 5%
would routinely reexcise. This difference between groups was
found to be statistically significant and the same significant
trend favoring not to reexcise was seen amongst surgeons
participating in weekly tumor boards and those trained in
surgical oncology. Another questionnaire study involving
200 breast surgeons in the United Kingdom showed less
variation in surgeon practices with 91% of respondents
favoring no further surgery if there was ADH at the margin
of excision, but both invasive and in situ disease were 10mm
clear of the margin [20].
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Table 1: Interobserver variability among pathologists in cases of borderline ductal proliferative lesions.
Investigator no. of pathologists/no. of slides reviewed Concordance rates (%)
6/24
5/5 agreed 0%
Rosai [21] 4/5 agreed 20%
3/5 agreed 50%
5/10
6/6 agreed 58%
Schnitt et al. [22]∗ 5/6 agreed 71%
4/6 agreed 92%
9/81
9/9 agreed 32%
Jain et al. [23] 8/9 agreed 52%
7/9 agreed 63%
∗Standardized criteria and formal education differentiating proliferative lesions provided to pathologist prior to reviewing slides.
Table 2: Atypical ductal hyperplasia (ADH) and ipsilateral breast tumor recurrence (IBTR).
Investigator
no. BCS
specimens
no. lumpectomy + for ADH
IBTR ADH (+)
no. (%)
IBTR in ADH (−)
no. (%)
Median Followup
(years)
Goldstein et al. [33] 94 54 3/54 (5.6)′ 0/36 (0)′′ 6.5
Fowble et al. [34] 460 99† 1/99 (1.0) 17/329 (5.2) 4.8
Greene et al. [35] 155∗ 87 0/87 (0%)∗∗ 1/68 (1.5)∗∗ 2.2
′ADH (+) at margin more recurrence than ADH (−) at margin P < 0.01.
′′Represents lesions negative for both ADH and COL.
†ADH involved somewhere in specimen, not specifically involving margin.
∗Lumpectomy performed for ADH, no malignancy in original specimen.
∗∗denotes malignancy development and not recurrence as initial lumpectomy was negative for malignancy.
There is a large practice variation amongst American
pathologists as well as demonstrated in the study conducted
by Ghofrani et al. [18], which was described earlier in
our paper. In addition to classifying the proliferative lesion
adjacent to DCIS as ADH or DCIS, the pathologists were also
asked what to do with the lesion if it involved the margin
of a BCS specimen. Regardless of whether the responders
diagnosed the lesion as ADH or DCIS, the final impact on
management was that 50.4% would recommend to reexcise
based on the lesion being present at the margin while 47%
would not reexcise. Of those that considered the lesion ADH,
37.7% recommended reexcision while only 28% of those who
considered the lesion DCIS recommended to reexcise.
3.4. Studies Evaluating ADH at the Margin of BCS Specimens.
There is a paucity of studies evaluating ADH at BCS
margins. Only two studies were found in the literature that
directly addressed the issue and they came to disagreeing
conclusions. One study reported compelling evidence for
reexcision if ADH involved the margin. It was a retrospective
review at a single institution (Mt Sinai Medical Center,
New York) that spanned 6 years (2000–2006) and sought to
determine the rate of residual disease when reexcision was
performed for ADH involving the margin of lumpectomies
performed for ADH or early stage breast cancer [36]. They
identified 44 lumpectomy specimens performed for ADH or
early stage breast cancer where ADH involved the margin (at
or within 1mm). 27 of the 44 cases underwent reexcision
and of the 27 that underwent reexcision and 26% had either
DCIS or invasive disease. They included the diagnosis of the
original lumpectomy to evaluate the rates of residual disease
based on lumpectomy for ADH versus DCIS versus invasive
disease. There were 7 lumpectomies for DCIS reexcised
for ADH involving the margin and of those, 2 reexcision
specimens had residual ADH (28.6%) and 4 had residual
DCIS (57%). There were 2 lumpectomies for invasive disease
reexcised for ADH involving the margin and both specimens
had residual ADH, but no DCIS or invasive disease identified
on reexcision specimens. Despite the small study sample,
they concluded that ADH at the margin of a lumpectomy
specimen is associated with a high rate of residual ADH or
cancer, and they recommend reexcision in all patients with
ADH involving the margin.
A different study by Goldstein et al. [33] investigated
whether ADH involving the margin of a BCS specimen
predicted IBTR. He retrospectively reviewed the slides of
94 patients treated with local excision followed by radiation
with particular attention to the presence of ADH at the
margins on the slides of final excision specimen. At a median
followup of 78 months, true recurrence (defined as recurring
in the same area as the original lumpectomy) developed
in 6 patients. DCIS and ADH within .2 cm of the margin
was associated with recurrence, but there was no association
with recurrence when ADH appeared alone. Importantly,
all 6 true recurrences occurred in cases where either ADH
alone, DCIS + ADH, or DCIS + cancerization of the lobules
(COL) was involving the margins of the initial specimen.
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One limitation in this study is the short followup time which
could be too short to detect recurrences in the specimens
with only ADH at the margin as the interval to development
of breast cancer in an ADH lesion is 8.2 years [31].
Greene et al. [35] performed an important study evalu-
ating ADH at the margin of lumpectomies performed solely
for ADH (none of lumpectomies evaluated were positive for
malignancy). They identified 87 lumpectomies with margins
positive for ADH. Of those with positive margins, none went
on to develop a malignancy. A significant limitation of this
study is a short followup of 26 months, and none of the
lumpectomies with an initial diagnosis of malignancy were
included in the study.
Some clinicians have used a study performed by Fowble
et al. [34] to support no reexcision for ADH at the
margin [20]. The Fowble study evaluated the influence of
proliferative lesions in the background benign breast tissue
of BCS specimens performed for stage I and II breast
cancer. In their study, they retrospectively reviewed the
pathology slides of 460 BCS specimens and found that 99
out of 460 specimens contained background atypical ductal
hyperplasia. The authors did not demonstrate an increased
risk of IBTRwithmedian followup 5.6 years in the specimens
with ADH compared to those specimens without ADH.
Unfortunately, this study did not specify where the ADH
was located in the specimen and did not identify which
specimens had ADH involving the margin. Rather, they just
confirmed the presence of ADH anywhere in the specimen,
and thus, it is not possible to make assumptions about
recurrence rates in those specimens where the ADH did
involve the margin. Although the study did not find IBTR
occurring at a significantly higher rate compared to the
non-ADH population, there were 3 IBTR observed in the
ADH population. It would be important to know if these
specimens contained ADH at the margin compared to the
cases where IBTR did not occur. Table 2 summarizes the
findings from the aforementioned studies.
4. Conclusion
In conclusion, there is not enough evidence to direct
reexcision when ADH is diagnosed at the margin of a BCS
specimen for early stage breast cancer. The work of our
paper did reveal that ADH at the margin of a BCS specimen
is a controversial pathological diagnosis subject to large
interobserver variability, and when this diagnosis is made
in the setting of a known cancer, it may actually represent
the peripheral extension of a neoplastic lesion. However,
if ADH represents low grade DCIS, recent data supports
that especially in ER positive tumors, when adjusting for
hormonal and radiation adjuvant treatment, the significance
associated with margin status and increased IBTR is less
clinically likely. Further studies with longer followup and
closer attention to ADH at the margin will be needed
to answer this question directly. In the meantime, it is
reasonable to consider reexcision of ADH at the surgical
margin especially in the face of low grade DCIS, but further
data is needed to provide more definitive recommendations.
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